Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Common Equity (2016 - 2025)

Historic Common Equity for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $9.7 million.

  • Ascendis Pharma A's Common Equity rose 1125.48% to $9.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.7 million, marking a year-over-year increase of 1125.48%. This contributed to the annual value of $9.4 million for FY2025, which is 800.1% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Common Equity stood at $9.7 million, which was up 1125.48% from -$203.5 million recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Common Equity peaked at $1.2 billion during Q3 2021, and registered a low of -$345.8 million during Q2 2024.
  • For the 5-year period, Ascendis Pharma A's Common Equity averaged around $59.9 million, with its median value being $8.4 million (2022).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 1388629.68% in 2021, then plummeted by 113528.92% in 2023.
  • Ascendis Pharma A's Common Equity (Quarter) stood at $1.0 billion in 2021, then crashed by 73.42% to $268.7 million in 2022, then crashed by 158.34% to -$156.8 million in 2023, then skyrocketed by 105.55% to $8.7 million in 2024, then grew by 11.25% to $9.7 million in 2025.
  • Its Common Equity was $9.7 million in Q4 2025, compared to -$203.5 million in Q3 2025 and -$212.3 million in Q2 2025.